AFMD Stock Recent News

Affimed N.V. (AFMD) Q4 2023 Earnings Call Transcript

MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2023 results and corporate update on March 28, 2024. The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET.

Affimed N.V. (AFMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Affimed (NASDAQ: AFMD ) stock is on the move Friday as investors prepare for the clinical-stage biopharmaceutical company's shares to undergo a reverse split later today. AFMD stock will go through a one-for-10 reverse stock split after markets close today.

While the topic of top penny stocks to buy may arouse controversy similar to apocryphal literature with spiritual implications. That might sound hyperbolic but generally, financial advisors shy away from the sector because of the extreme risks involved.

MANNHEIM, Germany, Dec. 04, 2023 (GLOBE NEWSWIRE) --  Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on December 11 at 1:30 p.m. PST / 4:30 p.m. EST to review clinical data presented from the combination trial of acimtamig with cord-blood derived NK cells during the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, CA. During the call, the Company will also provide a clinical data update from the AFM24-102 trial.

Affimed N.V. (NASDAQ:AFMD ) Q3 2023 Results Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Alexander Fudukidis - Director and Head of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Angus Smith - Chief Financial Officer Wolfgang Fischer - Chief Operating Officer Conference Call Participants Srikripa Devarakonda - Truist Securities Li Watsek - Cantor Fitzgerald Daina Graybosch - Leerink Partners Yanan Zhu - Wells Fargo Bradley Canino - Stifel Financial Yale Jen - Laidlaw & Company Sean Lee - H.C.

MANNHEIM, Germany, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2023 results and corporate update on Tuesday, November 14, 2023. The Company will host a conference call at 8:30 a.m. EST / 14:30 CET.

MANNHEIM, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the Company's management will participate in the following investor conferences during the month of November 2023.

Affimed N.V. (AFMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.